- Home
- CRBP vs SOPH Comparison
CRBP vs SOPH Comparison
Compare CRBP & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- SOPH
- Stock Information
- Founded
- CRBP 2009
- SOPH 2011
- Country
- CRBP United States
- SOPH Switzerland
- Employees
- CRBP N/A
- SOPH N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBP Health Care
- SOPH Health Care
- Exchange
- CRBP Nasdaq
- SOPH Nasdaq
- Market Cap
- CRBP 227.3M
- SOPH 247.0M
- IPO Year
- CRBP N/A
- SOPH 2021
- Fundamental
- Price
- CRBP $16.73
- SOPH $3.13
- Analyst Decision
- CRBP Strong Buy
- SOPH Strong Buy
- Analyst Count
- CRBP 7
- SOPH 3
- Target Price
- CRBP $65.86
- SOPH $7.00
- AVG Volume (30 Days)
- CRBP 346.4K
- SOPH 30.7K
- Earning Date
- CRBP 11-07-2024
- SOPH 11-05-2024
- Dividend Yield
- CRBP N/A
- SOPH N/A
- EPS Growth
- CRBP N/A
- SOPH N/A
- EPS
- CRBP N/A
- SOPH N/A
- Revenue
- CRBP N/A
- SOPH $64,488,000.00
- Revenue This Year
- CRBP N/A
- SOPH $7.34
- Revenue Next Year
- CRBP N/A
- SOPH $20.25
- P/E Ratio
- CRBP N/A
- SOPH N/A
- Revenue Growth
- CRBP N/A
- SOPH 9.85
- 52 Week Low
- CRBP $4.00
- SOPH $2.70
- 52 Week High
- CRBP $61.90
- SOPH $7.37
- Technical
- Relative Strength Index (RSI)
- CRBP 37.25
- SOPH 39.02
- Support Level
- CRBP $15.65
- SOPH $3.40
- Resistance Level
- CRBP $17.18
- SOPH $3.99
- Average True Range (ATR)
- CRBP 1.26
- SOPH 0.26
- MACD
- CRBP 0.35
- SOPH -0.05
- Stochastic Oscillator
- CRBP 21.09
- SOPH 0.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.